The global immunotoxins market share analysis is poised for significant growth, with its valuation expected to reach USD 159.2 million by 2025 and further expand to USD 410.2 million by 2035, at a ...

TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

Geoffrey Shouse, DO, PhD, discusses the growing interest in bispecific antibodies within the field of oncology.

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

Discover the newly identified proteins to predict ICANS, improving the safety of CAR-T cell therapy by identifying high-risk ...

PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today ...